Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Boundless Bio Inc
(NQ:
BOLD
)
3.146
+0.156 (+5.22%)
Streaming Delayed Price
Updated: 10:37 AM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
14,711
Open
3.090
Bid (Size)
3.140 (1)
Ask (Size)
3.180 (2)
Prev. Close
2.990
Today's Range
3.009 - 3.150
52wk Range
2.820 - 14.72
Shares Outstanding
45,783,265
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
November 05, 2024
From
Boundless Bio, Inc.
Via
GlobeNewswire
Boundless Bio Announces Departure of Chief Financial Officer
October 14, 2024
From
Boundless Bio, Inc.
Via
GlobeNewswire
Performance
YTD
-77.92%
-77.92%
1 Month
-1.07%
-1.07%
3 Month
+0.84%
+0.84%
6 Month
-68.54%
-68.54%
1 Year
-77.92%
-77.92%
More News
Read More
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
September 11, 2024
From
Boundless Bio, Inc.
Via
GlobeNewswire
BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024
May 13, 2024
Via
InvestorPlace
BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024
August 12, 2024
Via
InvestorPlace
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
August 12, 2024
From
Boundless Bio, Inc.
Via
GlobeNewswire
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Boundless Bio
Via
Business Wire
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
May 13, 2024
From
Boundless Bio
Via
Business Wire
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
May 06, 2024
From
Boundless Bio
Via
Business Wire
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
April 11, 2024
From
Boundless Bio
Via
Business Wire
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
April 08, 2024
From
Boundless Bio
Via
Business Wire
Bayer-Backed Boundless Bio Falls After IPO
March 31, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.